KAC is a contract research organization (CRO), that supports development of pharmaceutical/regenerative medical products. The company provides an end-to-end system, which covers the entire Non-clinical study process— supplying laboratory animals, conducting animal studies, performing evaluations, and analyzing results— entirely in-house.
KAC offers a range of toxicity studies with a focus on single-dose and repeated-dose toxicity tests. The company also conducts local irritation studies (rabbit), sensitization testing, and other evaluations required for the non-clinical assessment of pharmaceuticals/regenerative medical products.
Flexible study designs with multiple animal species such as mice and rats are available. This enables a tailored proposal to each client's study needs.
KAC conducts biological safety studies compliant with ISO 10993, including cytotoxicity and sensitization tests, supporting non-clinical evaluations for medical devices and regenerative medical products.
The company provides reliable safety data generated under test systems which are aligned with international standards. Examples include a variety of irritation assays and material reactivity assessments. Evaluation items can be customized according to the characteristics of client’s compound.
KAC is a GLP(Good Laboratory Practice) compliant facility. They provide all of our non-clinical studies according to the GLP standard. The organization maintains appropriately managed facilities and operations to ensure the reliability and traceability of study data.
KAC is recognized as a research institution who continues their work to improve quality of each study.
KAC supports studies using the rat Chronic Constriction Injury (CCI) model, one of the most widely used models for neuropathic pain. By applying mild constriction to peripheral nerves, changes in pain-related behaviors can be evaluated.
This model is commonly used for pharmacological efficacy studies, such as measuring responses to mechanical stimuli via the von Frey test. It enables the assessment of candidate therapeutics for neuropathic pain.
Reference:
https://www.kacnet.co.jp/service/bioscience/pain-test/pain-test.html
No case studies were available on the official website.
| Address | 40 Nishi Gekko-cho, Nishinokyo, Nakagyo-ku, Kyoto, Japan |
|---|---|
| Tel | 075-801-9311 |
| Website | https://www.kacnet.co.jp/ |
In non-clinical development, the choice of contract research organization shapes the quality of the data and the time it takes to reach the next decision. Below, three CROs are introduced by the type of study they support: pharmacology (efficacy) studies, safety studies, and pharmacokinetic (PK/PD) studies. Each summary describes the services the company offers so that you can match a provider to your target and development objective.
SMC Laboratories is a specialized non-clinical CRO focused on in vivo pharmacology and efficacy studies using disease-relevant animal models, particularly in fibrosis, inflammation, metabolic diseases, and oncology.
SMC Laboratories offers models covering the liver, lung, kidney, intestine, and oncology. Its portfolio includes the proprietary STAM™ model for MASH, fibrosis, and hepatocellular carcinoma.
Study plans are developed around the target biology, mechanism of action, disease stage, and development objective. Pharmacological endpoints can be combined with histopathology, biomarkers, and disease-specific readouts.
With experience from more than 1,000 studies for clients in 30 countries, SMC Laboratories supports programs from target validation and candidate selection through in vivo proof-of-concept studies.
Charles River provides non-clinical toxicology and safety assessment services for programs ranging from exploratory safety studies to IND-enabling development.
Services include single- and repeat-dose toxicology, dose-range finding, and general toxicology studies across multiple species and administration routes.
Charles River supports both non-GLP and GLP studies, allowing sponsors to progress from early safety characterization to studies intended for regulatory submissions.
Toxicology studies can be integrated with toxicokinetics, clinical pathology, histopathology, and safety pharmacology to support interpretation and IND-enabling safety packages.
Inotiv provides integrated PK/PD, DMPK, and bioanalytical services to characterize drug exposure and its relationship with pharmacological response.
PK studies characterize exposure, half-life, clearance, and other pharmacokinetic parameters needed to understand how a candidate behaves in the selected model.
Pharmacokinetic data can be combined with pharmacodynamic endpoints and bioanalysis to evaluate the relationship between drug exposure and pharmacological response.
Integrated DMPK, pharmacology, and safety information supports candidate comparison, dose selection, dosing-frequency optimization, and decisions about subsequent preclinical development.